60 Degrees Pharmaceuticals (NASDAQ:SXTP) Price Target Lowered to $4.20 at Ascendiant Capital Markets

60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target decreased by analysts at Ascendiant Capital Markets from $11.20 to $4.20 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price objective points to a potential upside of 132.04% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright boosted their price target on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen upgraded 60 Degrees Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.10.

60 Degrees Pharmaceuticals Trading Up 2.3%

Shares of 60 Degrees Pharmaceuticals stock opened at $1.81 on Thursday. The company’s 50-day moving average price is $2.73 and its two-hundred day moving average price is $3.75. 60 Degrees Pharmaceuticals has a 52 week low of $1.29 and a 52 week high of $17.68. The stock has a market cap of $4.78 million, a PE ratio of -0.13 and a beta of 3.27.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.